Document:

NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE
EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE
HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE
144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

PRESSURE
BIOSCIENCES, inc.

 

amendment
number 1 to october 26, PROMISSORY NOTE

 

	Original
    Principal: US$2,000,000	Original
    Issue Date: October 26, 2016
	 	 
	Amendment
    No. 1	 
	Principal:
    US$3,000,000	Amendment
    No. 1 Issue Date: May 2, 2017

 

WHEREAS, PRESSURE
BIOSCIENCES, INC., a corporation incorporated under the laws of the Commonwealth of Massachusetts and located at 14 Norfolk
Avenue, South Easton, MA 02375 (the “Company”) previously issued a Promissory Note (the “Original Note”)
on October 26, 2016 (the “Original Issue Date”), in favor of__, an individual residing at (the “Holder”)
for the principal sum of Two Million United States Dollars (US$2,000,000);

 

WHEREAS,
pursuant to oral agreements, the Holder provided Revolver Advances of $250,000 to the Company on March 23, 2017 and $250,000 on
May 2, 2017, with such Revolver Advances, when combined with all other previous Revolver Advances pursuant to the Original Note,
aggregating to a principal sum of Two Million Five Hundred Thousand United States Dollars (US$2,500,000) (the “March
and May Advances”);

 

WHEREAS,
the Company and the Holder wish to clarify that the March and May Advances were requested and made pursuant to a planned amendment
to the Original Note; and

 

WHEREAS,
the Company and the Holder wish to amend the Original Note with such amendment having an issue date of May 2, 2017 (this “Amendment
Number 1”) and the Original Note having the Original Issue Date.

 

    	 	 	 

    	 		 

    

 

NOW,
THEREFORE, in consideration of, among other things, the premises, representations, respective covenants and agreements contained
herein, each party hereby agrees to the following:

 

	 	1.	Capitalized
    terms used, but not defined, herein, shall have the meanings ascribed to such terms in the Original Note.
	 	 	 
	 	2.	In
    consideration for entering into this Amendment Number 1, the Company agrees to issue to the Holder 500,000 restricted shares
    of the Company’s common stock within seven (7) Business Days of May 2, 2017.
	 	 	 
	 	3.	The
    definition of Principal Amount in the Original Note is changed to Three Million United States Dollars (US$3,000,000).
	 	 	 
	 	4.	The
    definition of Trigger Date in Section 1(c)(i) of the Original Note is changed to “July 25, 2017 (such date, the “Trigger
    Date”);”.
	 	 	 
	 	5.	Section
    4 of the Original Note is replaced in its entirety and shall read as follows:

 

	 	a.	4.
    Qualified Offering. On or prior to May 9, 2017, the Holder shall inform the Company its request to be repaid in cash,
    on the closing of the Qualified Offering, an exact amount (up to $1,000,000) of the outstanding balance of the Note (principal
    and interest). The repayment shall be made from the proceeds of the Qualified Offering within five (5) Business Days from
    the closing of the Qualified Offering. Any portion of the Note not repaid in cash from the proceeds of the Qualified Offering
    shall be entirely repaid (including principal and interest) via the conversion, on the closing of the Qualified Offering,
    into unregistered Series S convertible preferred stock of the Company at a purchase price that is eighty percent (80%) of
    the purchase price of the securities sold by the Company in connection with the Qualified Offering and unregistered warrants
    in like form to the warrants issued in the Qualified Offering (except that the warrants issued to the Holder will have a cashless
    exercise provision) equal to _% (the same percentage of warrant coverage issued in the Qualified Offering) of the stock underlying
    the Series S on an as-converted basis, at an exercise price equal to eighty percent (80%) of the exercise price of the warrants
    issued in the Qualified Offering. 

 

	 	6.	The
    definition of Exercise Price in Section 5(b) of the Original Note is changed to “with an exercise price of the lower
    of (i) forty cents ($0.40) or (ii) the per share purchase price of the shares of common stock sold in the Qualified Offering
    (the “Exercise Price”).”
	 	 	 
	 	7.	A
    new Section 13(l) is added to the Original Note as follows:

 

	 	a.	(l)
    Conflict between This Note and Warrants. In the case of any conflict between this Note and the warrants issued pursuant
    to Section 5(b) of this Note, the terms of this Note shall govern. For the avoidance of doubt, irrespective of the exercise
    price listed in Section 1(b) of the warrants issued pursuant to Section 5(b) of this Note, the Exercise Price of such warrants
    shall be as defined in this Note.

 

    	 	 2	 

    	 		 

    

 

	 	8.	All
    other terms and conditions of the Original Note shall remain in full force and effect, including, for the avoidance of doubt,
    the Company’s obligation to pay a Warrant Fee pursuant to Section 5(b) within seven business days of the date upon which
    the Holder makes a principal advance to the Company.
	 	 	 
	 	9.	This
    Amendment Number 1 may be executed in any number of counterparts and by the different signatories hereto on separate counterparts,
    each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same
    instrument. This Amendment Number 1 may be executed by facsimile transmission, PDF, electronic signature or other similar
    electronic means with the same force and effect as if such signature page were an original thereof.

 

[Signature
page follows]

 

    	 	 3	 

    	 		 

    

 

IN
WITNESS WHEREOF, this Amendment Number 1 has been executed and delivered on the Amendment No. 1 Issue Date specified above.

 

	 	COMPANY:
	 	 
	 	PRESSURE
    BIOSCIENCES, INC.
	 	 	 
	 	By:	 
	 	Name:	Richard
T. Schumacher
	 	Title:	President
    and CEO
	 	 	 
	 	HOLDER:
	 	 	 
	 	 	 

 

[signature
page to Amendment Number 1]

 

    	 	 4	 

    	 		 

    

 

aNEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE
EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE
HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE
144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

PRESSURE
BIOSCIENCES, inc.

 

PROMISSORY
NOTE

 

	US$630,000	Issue Date: May 19, 2017

 

This Promissory Note (the
“Note”) is duly authorized and issued by PRESSURE BIOSCIENCES, inc.,
a corporation incorporated under the laws of the Commonwealth of Massachusetts and located at 14 Norfolk Avenue, South Easton,
MA 02375 (the “Company”), in favor of , an individual residing at (the “Holder”).

 

FOR
VALUE RECEIVED, the Company promises to pay to the order of the Holder the principal sum of Six Hundred Thirty Thousand United
States Dollars (US$630,000) (the “Principal Amount”), by the forty-fifth (45) day anniversary of the date hereof
(the “Maturity Date”), and to pay guaranteed interest of $63,000 on all outstanding amounts hereunder on or
prior to the Maturity Date, and in addition to pay an Origination Fee of Thirty-two Thousand United States Dollars ($32,000) in
accordance with the terms hereof.

 

1.
Principal and Interest.

 

(a)
Payment of Principal. The principal amount of this Note shall be paid in full on the Maturity Date, unless otherwise paid
prior to the Maturity Date, at the option of the Company.

 

(b)
Payment of Interest. Interest on the principal balance of this Note shall paid in full on the Maturity Date, unless otherwise
paid prior to the Maturity Date, at the option of the Company. With the exception of Default Interest, interest shall be in the
form of one-time interest charges assessed in full as of the date of the principal advance and shall not be assessed per annum.

 

    	 

    	 

    

 

(c)
Payment of Origination Fee. An origination fee of $32,000 shall be paid in full on the Maturity Date, unless otherwise
paid prior to the Maturity Date, at the option of the Company.

 

(d)
Payment of Default Interest. Any amount of principal or interest on this Note which is not paid when due shall bear interest
at the rate of twenty percent (20%) per annum (the “Default Rate”) until such past due amount is paid.

 

(e)
General Payment Provisions. All payments of principal and interest on this Note shall be made in lawful money of the United
States of America by check or wire transfer to such account as the Holder or the Company (as applicable) may designate. Whenever
any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead
be due on the next succeeding Business Day. For purposes of this Note, “Business Day” shall mean any day other
than a Saturday, Sunday or a day on which commercial banks in the State of New York are authorized or required by law or executive
order to remain closed.

 

2.
Holder Representations and Warranties. Holder hereby represents, warrants and agrees with the Company that:

 

(a)
Standing of Holder. Holder has the legal capacity and power to enter into this Note.

 

(b)
Authorization and Power. Holder has the requisite power and authority to enter into and perform this Note and to advance
the principal amount provide hereunder and accept the Note. The execution, delivery and performance of this Note by Holder, and
the consummation by Holder of the transactions contemplated hereby, have been duly authorized by all necessary action, and no
further consent or authorization of Holder is required. This Note has been duly authorized, executed and delivered by Holder and
constitutes, or shall constitute, when executed and delivered, a valid and binding obligation of Holder, enforceable against Holder
in accordance with the terms hereof.

 

(c)
Information on Holder. Holder is an “accredited investor,” as such term is defined in Regulation D promulgated
by the Commission under the 1933 Act, is experienced in investments and business matters, has made investments of a speculative
nature and has purchased securities of United States publicly-owned companies in private placements in the past and, with Holder’s
representatives, has such knowledge and experience in financial, tax and other business matters as to enable Holder to utilize
the information made available by the Company to evaluate the merits and risks of, and to make an informed investment decision
with respect to, the proposed purchase, which Holder hereby agrees represents a speculative investment. Holder has the authority
and is duly and legally qualified to purchase and own the Note. Holder is able to bear the risk of such investment for an indefinite
period and to afford a complete loss thereof.

 

    	2 

    	 

    

 

(d)
Purchase of Note. Holder will purchase the Note for Holder’s own account for investment and not with a view toward,
or for resale in connection with, the public sale or any distribution thereof in violation of the Securities Act of 1933, as amended
(the “Securities Act”) or any applicable state securities law, and has no direct or indirect arrangement or
understandings with any other person or entity to distribute or regarding the distribution of the Note.

 

(e)
Highly Speculative Investment. Holder acknowledges and agrees that a purchase of the Note is highly speculative and involves
significant risks and that the Note should not be purchased if Holder cannot afford the loss of Holder’s entire investment.
The business objectives of the Company are speculative, and it is possible that the Company may be unable to achieve them. Holder
understands that Holder may be unable to realize a substantial return on the purchase of the offered Note, or any return whatsoever,
and may lose Holder’s entire investment.

 

(f)
Compliance with Securities Act. Holder understands and agrees that the Note has not been registered under the Securities
Act or any applicable state securities laws by reason of their issuance in a transaction that does not require registration under
the Securities Act (based in part on the accuracy of the representations and warranties of Holder contained herein).

 

(g)
Communication of Offer. Holder has a preexisting personal or business relationship with the Company or one or more of its
directors, officers, advisors or control persons, and the offer to issue the Note was directly communicated to Holder by the Company.
At no time was Holder presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement,
or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection
and concurrently with such communicated offer.

 

(h)
No Governmental Endorsement. Holder understands that no United States federal or state agency or any other governmental
or state agency has passed on or made recommendations or endorsement of the Note, or the suitability of the investment in the
Note, nor have such authorities passed upon or endorsed the merits of the offering of the Note.

 

(i)
Information. Holder and its advisors, if any, have been furnished with all materials relating to the business, finances
and operations of the Company and materials relating to the offer and sale of the Note that have been requested by Holder. Holder
and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other
due diligence investigations conducted by Holder or its advisors, if any, or its representatives shall modify, amend or affect
Holder’s right to rely on the Company’s representations and warranties contained herein. Holder understands that its
investment in the Note involves a high degree of risk and the Holder is able to afford a complete loss of such investment. Holder
has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect
to its acquisition of the Note.

 

(j)
Reliance on Exemptions. The Holder understands that the Note is being offered and sold or assigned to it in reliance on
specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
is relying in part upon the truth and accuracy of, and Holder’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of Holder set forth herein in order to determine the availability of such exemptions and the
eligibility of Holder to acquire the Note.

 

    	3 

    	 

    

 

3.
Company Representations and Warranties. The Company represents, warrants and agrees with Holder that:

 

(a)
Due Incorporation. The Company is a corporation duly incorporated, validly existing and in good standing under the laws
of the jurisdiction of its incorporation;

 

(b)
Authority; Enforceability. This Note has been duly authorized, executed and delivered by the Company and is the valid and
binding agreement of the Company, enforceable in accordance with their terms, except as may be limited by bankruptcy, insolvency,
moratorium or other similar laws affecting the enforcement of creditors’ rights generally, or principles of equity. The
Company has full corporate power and authority necessary to enter into and deliver this Note and to perform its obligations thereunder;

 

(c)
Encumbrances. Upon issuance, the Note (i) shall be free and clear of any security interests, liens, claims or other encumbrances;
(ii) shall have been duly and validly issued, fully paid and non-assessable; and (iii) will not subject the holders thereof to
personal liability by reason of being such holders;

 

(d)
Litigation. There is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or investigation
before or by any court, governmental agency or body having jurisdiction over the Company including, without limitation, any such
that would materially affect the execution by the Company or the complete and timely performance by the Company of its obligations
under this Note;

 

(e)
No General Solicitation. Neither the Company, nor any of its affiliates, nor any person or entity acting on its or their
behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities
Act) in connection with the offer or sale of the Note;

 

(f)
Investment Company. The Company is not an “investment company” within the meaning of the Investment Company
Act of 1940, as amended; and

 

(g)
Full Disclosure. No representation or warranty or other statement made by the Company in this Note in connection with the
contemplated transactions contains any untrue statement of material fact or omits to state a material fact necessary to make the
representations and warranties set forth herein, in light of the circumstances in which they were made, not misleading.

 

4.
Broker’s Commission/Finder’s Fee. With the exception of Garden State Securities, Inc. which is being paid five
percent (5%) of all principal amounts advanced in connection herewith, there are no parties entitled to receive fees, commissions,
finder’s fees, due diligence fees or similar payments in connection with the consummation of the transactions contemplated
hereby. Each party hereto agrees to indemnify the other against and hold the other harmless from any and all liabilities to any
persons claiming brokerage commissions or similar fees on account of services purported to have been rendered on behalf of the
indemnifying party in connection with this Note or the transactions contemplated hereby and arising out of the indemnifying party’s
actions.

 

    	4 

    	 

    

 

5.
Events of Default. The term “Event of Default” shall mean any of the events set forth in this Section
(the term “Company” for this purpose shall include all subsidiaries of the Company):

 

(a)
Non-Payment of Obligations. The Company shall default in the payment of the Principal Amount of, or accrued but unpaid
interest on, this Note as and when the same shall become due and payable, whether by acceleration or otherwise, and the Holder
shall have delivered written notice to the Company and provided a fifteen (15) day opportunity to cure such default.

 

(b)
Non-Performance of Covenants. The Company shall default in the due observance or performance of any covenant set forth
herein, which default shall continue uncured for ten (10) days after notice thereof.

 

(c)
Bankruptcy, Insolvency, etc. The Company shall (i) apply for, consent to, or acquiesce in, the appointment of a trustee,
receiver, sequestrator or other custodian for the Company or any of its property, or make a general assignment for the benefit
of creditors; (ii) in the absence of such application, consent or acquiesce in, permit or suffer to exist the appointment of a
trustee, receiver, sequestrator or other custodian for the Company or for any part of its property and that is not dismissed within
sixty (60) days; or (iii) take any corporate or other action authorizing any of the foregoing.

 

6.
Remedies. If any Event of Default shall occur for any reason, whether voluntary or involuntary, the Holder may, upon expiration
of any stated grace period (if any) and upon written notice to the Company, declare all or any portion of the outstanding principal
amount of the Note and all accrued but interest thereon, to be due and payable and any or all other obligations hereunder to be
due and payable, whereupon the full unpaid principal amount hereof, and any and all other such obligations which shall be so declared
due and payable shall be and become immediately due and payable, without further notice, demand, or presentment. The Holder shall
have all rights available to it at law or in equity.

 

7.
Default Interest; Miscellaneous. If any Event of Default shall occur, the Principal Amount of this Note, all accrued but
unpaid interest thereon, and all other obligations hereunder shall accrue interest at the Default Rate. The
Holder may assess reasonable attorneys’ fees, paralegals’ fees and costs and expenses
incurred or anticipated by the Holder in collecting or enforcing payment hereof (whether
such fees, costs or expenses are incurred in negotiations, all trial and appellate levels, administrative proceedings, bankruptcy
proceedings or otherwise), and together with all other sums due by the Company hereunder, all without any relief whatsoever from
any valuation or appraisement laws, and payment thereof may be enforced and recovered in whole or in part at any time by one or
more of the remedies provided to the Holder at law, in equity, or under this Note. In connection with the Holder’s rights
hereunder upon an Event of Default, the Holder need not provide, and the Company hereby waives, any presentment, demand, protest
or other notice of any kind, and the Holder may immediately enforce any and all of its rights and remedies hereunder and all other
remedies available to it in equity or under applicable law.

 

    	5 

    	 

    

 

8.
Miscellaneous.

 

(a)
Parties in Interest. All covenants, agreements and undertakings in this Note binding upon the Company or the Holder shall
bind and inure to the benefit of the successors and permitted assigns of the Company and the Holder, respectively, whether so
expressed or not.

 

(b)
Law Governing this Note. This Note shall be governed by the laws of the State of Illinois without regard to any principles
of conflicts of law. Each of the parties hereby irrevocably consents and agrees that any legal or equitable action or proceeding
arising under or in connection with this Note shall be brought in the federal or state courts located in Illinois, and by execution
and delivery of this Note, irrevocably submits to and accepts the jurisdiction of said courts, waives any defense that such court
is not a convenient forum, and consent to any service of process method permitted by law.

 

(c)
Waiver of Jury Trial. THE PARTIES HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHTS THEY MAY HAVE TO
A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS NOTE OR ANY OTHER
DOCUMENT OR INSTRUMENT EXECUTED AND DELIVERED IN CONNECTION HEREWITH, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS
(WHETHER VERBAL OR WRITTEN), OR ACTIONS OF THE HOLDER OR THE COMPANY. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE HOLDER’S
PURCHASING THIS NOTE.

 

(d)
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder
shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered
or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid,
or (iv) transmitted by hand delivery or facsimile, addressed as set forth in the preamble paragraph hereto or to such other address
as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to
be given hereunder shall be deemed effective (a) upon hand delivery at the address designated in the preamble paragraph hereto
(if delivered on a business day during normal business hours where such notice is to be received), or the first business day following
such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or
(b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address,
or upon actual receipt of such mailing, whichever shall first occur.

 

    	6 

    	 

    

 

(e)
No Waiver. No delay in exercising any right hereunder shall be deemed a waiver thereof, and no waiver shall be deemed to
have any application to any future default or exercise of rights hereunder.

 

(f)
Modification and Severability. If, in any action before any court or agency legally empowered to enforce any provision
contained herein, any provision hereof is found to be unenforceable, then such provision shall be deemed modified to the extent
necessary to make it enforceable by such court or agency. If any such provision is not enforceable as set forth in the preceding
sentence, the unenforceability of such provision shall not affect the other provisions of this Note, but this Note shall be construed
as if such unenforceable provision had never been contained herein.

 

(g)
Entire Agreement. This Note constitutes the entire agreement between the parties hereto with respect to the subject matter
hereof and may be amended only by a writing executed by both parties hereto. Neither the Company nor Holder has relied on any
representations not contained or referred to in this Note and the documents delivered herewith.

 

(h)
Counterparts/Execution. This Note may be executed in any number of counterparts and by the different signatories hereto
on separate counterparts, each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute
but one and the same instrument. This Note may be executed by facsimile transmission, PDF, electronic signature or other similar
electronic means with the same force and effect as if such signature page were an original thereof.

 

(i)
Severability. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid
or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.

 

(j)
Counsel; Ambiguities. Each party and its counsel have participated fully in the review and revision of this Note and any
documents executed in connection therewith. The parties understand and agree that any rule of construction to the effect that
ambiguities are to be resolved against the drafting party shall not apply in interpreting this Note and any documents executed
in connection therewith. The language in this Note and any documents executed in connection therewith shall be interpreted as
to its fair meaning and not strictly for or against any party.

 

(k)
Captions. The captions of the various sections and paragraphs of this Note have been inserted only for the purposes of
convenience; such captions are not a part of this Note and shall not be deemed in any manner to modify, explain, enlarge or restrict
any of the provisions of this Note.

 

[Signature
page follows]

 

    	7 

    	 

    

 

IN
WITNESS WHEREOF, this Note has been executed and delivered on the date specified above.

 

	 	COMPANY:
	 	 
	 	PRESSURE BIOSCIENCES, INC.
	 	 	 
	 	By:	 
	 	Name:	Richard
    T. Schumacher
	 	Title:	President
    and CEO
	 	 	 
	 	HOLDER:
	 	 

                                                                                 

 

[signature
page to Promissory Note]

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]